Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Pompe Disease Infantile-Onset

Tundra lists 4 Pompe Disease Infantile-Onset clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

AVAILABLE

NCT04327973

Expanded Access for ATB200/AT2221 for the Treatment of IOPD

This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200/AT2221.

Gender: All

Ages: 0 Years - 17 Years

Updated: 2026-10-27

2 states

Pompe Disease Infantile-Onset
RECRUITING

NCT05619900

Registry of Patients Diagnosed With Lysosomal Storage Diseases

This is an international prospective and retrospective registry of patients with Lysosomal Storage Diseases (LSDs) to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with LSDs.

Gender: All

Ages: Any - 64 Years

Updated: 2026-04-08

1 state

Mucopolysaccharidosis I
Mucopolysaccharidosis II
Mucopolysaccharidosis IV A
+5
RECRUITING

NCT04532047

PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)

For detailed information, please view our study website: https://pearltrial.ucsf.edu/ The investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.

Gender: FEMALE

Ages: 18 Years - 50 Years

Updated: 2026-03-17

1 state

MPS I
MPS II
MPS IVA
+6
ACTIVE NOT RECRUITING

NCT05793307

Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug

This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as potential gene therapy for Pompe disease. Patients diagnosed with infantile-onset Pompe disease who are younger than 6 months old will be studied.

Gender: All

Ages: Any - 6 Months

Updated: 2025-07-03

Pompe Disease Infantile-Onset